Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Aemcolo

(Rifamycin-containing regimen)

Small molecule

CCosmo Technologies Ltd

0

Indications

1

Total Trials

1

Active Trials

0

Competitors

1

FDA Application

NDA/BLA/ANDA regulatory filings

Timeline

Expected Milestones

Q4 2026

Post-ApprovalRecruiting

Kidney Transplant

NCT05588492

Clinical

Trials by Indication[1]

Kidney Transplant1 trial

The Safety, Completion Rate and Prevention Effect by Rifamycin-containing Regimens for Latent Tuberculosis Infection in Patients With Kidney Transplantation: a Prospective Intervention Pilot Study

Recruiting·NNational Taiwan University Hospital·Phase 4·NCT05588492·500 enrolled

Regulatory

FDA Approval Timeline[3]

Nov 16, 2018

AEMCOLO

NDA NDA210910

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Rifamycin-containing regimen. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Rifamycin-containing regimen compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
OpenFDA — FDA approval records (NDA NDA210910). U.S. Food & Drug Administration.
[4]
SEC EDGAR — Cosmo Technologies Ltd company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Company: CCosmo Technologies Ltd

Related News